Perrigo (PRGO)
Makes consumer self-care products through Americas and international operating segments.
Something off on this page? Send us feedback.
Sells consumer self-care products through Consumer Self-Care Americas and Consumer Self-Care International. The company combines a store-brand manufacturing heritage with international businesses, particularly in Europe and Australia.
Builds consumer self-care products on a store-brand model established from its early medicine-packaging business. Consumer Self-Care Americas serves the United States and Canada, while Consumer Self-Care International spans markets beyond them, primarily Europe and Australia.
Manufacturing developed from repackaging medicines and household goods to affordable healthcare products, and acquisitions including Omega Pharma and HRA Pharma expanded the international platform. Its latest annual-report portfolio plan included reviews of Oral Care and Infant Formula and an agreement to sell certain Dermacosmetics businesses. Ireland incorporation following the Elan acquisition defines the company's legal structure.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Nov 6, 2025 | Canaccord Genuity | Reiterate | Rating: —Target: $40 | Target: $20 |
| Nov 6, 2025 | JP Morgan | Downgrade | ||
| Oct 27, 2025 | Jefferies | Reiterate | Rating: —Target: $30 | Target: $23 |
| Jan 14, 2025 | Argus | Downgrade | ||
| Jan 6, 2025 | Piper Sandler | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 27, 2026Cash & short-term investments $399.7M · Total debt $3.29B · Total assets $7.61B · Shareholders' equity $2.52B
- Revenue
- $1.02B
- Operating income
- $23.5M
- Net income
- $74.5M
HistoryDividendAnnual yield
| Institutions | 117.31% | 162.78M shares | |
|---|---|---|---|
| 352 holders · as of Jun 30, 2026 | |||
| Insiders | 7.50% | 10.41M shares | |
| 21 holders · as of Sep 15, 2026 | |||
| Strategic holders | 5.75% | 7.98M shares | |
| 1 holder · as of Feb 7, 2018 | |||
| Adds to | 130.56% | ||
138.77M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 130.56%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.36% | 22.70M | as of Jun 30, 2026 |
Neuberger Berman Group LLCInstitution | 7.70% | 10.68M | as of Jun 30, 2026 |
Barrow Hanley Global InvestorsInsider | 7.08% | 9.83M | filed Feb 15, 2023 |
Vanguard Portfolio Management LLCInstitution | 6.52% | 9.05M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 6.27% | 8.70M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 12, 2025 | Geoffrey M. Parker | director | +7,500 | $14.18 |
- Haleon (ADR)
Global consumer-health rival across pain, oral care and digestive health
- Kenvue
Branded self-care rival in respiratory, allergy and skin health
- Procter & Gamble
Branded OTC and personal-care competitor led by Vicks and Pepto-Bismol
- Abbott
Infant-formula competitor through the Similac nutrition portfolio
- Dr. Reddy's Laboratories (ADR)
Generic-medicines manufacturer with category-specific OTC overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Perrigo | $14.28 | +1.03% | $1.96B | — | 6.0 | 0.5 | −3.2% |
| Haleon (ADR) | $9.30 | −0.69% | $41.22B | 19.5 | — | 2.8 | +3.7% |
| Kenvue | $17.93 | +1.44% | $33.93B | 20.3 | 15.0 | 2.2 | +3.0% |
| Procter & Gamble | $147.38 | +0.89% | $347.33B | 22.1 | 21.1 | 4.0 | +1.5% |
| Abbott | $104.00 | +0.99% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| Dr. Reddy's Laboratories (ADR) | $12.58 | +1.41% | $10.33B | 29.8 | 33.5 | 3.0 | −15.5% |
| Median | 22.1 | 19.5 | 3.0 | +3.0% |